Beta Drugs Ltd: Stock Analysis & Fundamentals

Updated this week

Beta Drugs Ltd (Pharma - API) — fundamental analysis, earnings data, and key metrics. PE: 27.4. ROE: 25.9%. This stock is not currently in the Nifty 500 momentum outperformers list.

Key Numbers

Current Price

₹1,165

Market Cap

1.2K Cr

Valuation

N/A

Other Top Pharma - API Stocks Beating Nifty 500

Senores Pharmaceuticals Ltd

Average

+8.4%

Ind-Swift Laboratories Ltd

← Back to Pharma - API Dashboard

Frequently Asked Questions: Beta Drugs Ltd

Based on publicly available financial data. This is educational research, not investment advice.

What were Beta Drugs Ltd's latest quarterly results?

Beta Drugs Ltd's latest quarterly results (Dec 2025) show

PAT Growth YoY: -4.8%
Revenue Growth YoY: -1.2%
Operating Margin: 19.5%

What is Beta Drugs Ltd's current PE ratio?

Beta Drugs Ltd's current PE ratio is 27.4x.

Current PE: 27.4x
Market Cap: 1.2K Cr

What is Beta Drugs Ltd's price-to-book ratio?

Beta Drugs Ltd's price-to-book ratio is 5.3x.

Price-to-Book (P/B): 5.3x
Book Value per Share: ₹219
Current Price: ₹1165

Is Beta Drugs Ltd a fundamentally strong company?

Beta Drugs Ltd's fundamental strength based on key financial ratios

Return on Capital (ROCE): 27.0%

Is Beta Drugs Ltd debt free?

Beta Drugs Ltd has a debt-to-equity ratio of N/A.

Total Debt: ₹146 Cr

What is Beta Drugs Ltd's return on equity (ROE) and ROCE?

Beta Drugs Ltd's return ratios over recent years

FY2023: ROCE 34.0%
FY2024: ROCE 33.0%
FY2025: ROCE 27.0%

Is Beta Drugs Ltd's cash flow positive?

Beta Drugs Ltd's operating cash flow is positive (FY2025).

Cash from Operations (CFO): ₹36 Cr
Free Cash Flow (FCF): ₹0 Cr
CFO/PAT Ratio: 86% (strong cash conversion)

What is Beta Drugs Ltd's dividend yield?

Beta Drugs Ltd currently does not pay a significant dividend (yield 0.00%).

Dividend Yield: 0.00%
Current Price: ₹1165

Who holds Beta Drugs Ltd shares — promoters, FII, DII?

Beta Drugs Ltd's shareholding pattern (Dec 2025)

Promoters: 64.9%
FII (Foreign): 1.1%
DII (Domestic): 1.9%
Public: 32.1%

Is promoter holding increasing or decreasing in Beta Drugs Ltd?

Beta Drugs Ltd's promoter holding has decreased recently.

Current Promoter Holding: 64.9% (Dec 2025)
Previous Quarter: 66.7% (Sep 2025)
Change: -1.83% (decreasing — worth monitoring)

Is Beta Drugs Ltd a new momentum entry or an established outperformer?

Beta Drugs Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.

Is Beta Drugs Ltd worth studying for long term investment?

Based on quantitative research signals, here is why Beta Drugs Ltd may be worth studying

Cash flow is positive — CFO ₹36 Cr

What is the investment thesis for Beta Drugs Ltd?

Beta Drugs Ltd investment thesis summary:

What is the future outlook for Beta Drugs Ltd?

Beta Drugs Ltd's forward outlook based on current data signals

Insufficient data for a forward assessment — monitoring for more signals

The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.